Skip to main content

Table 1 Relationship between heregulin, ErbB1-4, pErbB1-4 and clinicopathological factors

From: Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer

  

Heregulin

EGFR

pEGFR

ErbB2

pErbB2

ErbB3

pErbB3

ErbB4

pErbB4

 

No.

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

No. (percent)

P value

Age

                   

 <66

78

38 (49)

NS

46 (59)

NS

27 (35)

NS

14 (18)

0.018

12 (15)

NS

28 (36)

NS

19 (24)

NS

17 (22)

NS

9 (12)

NS

 ≥66

77

33 (43)

 

33 (43)

 

23 (30)

 

27 (35)

 

18 (23)

 

36 (47)

 

21 (27)

 

16 (21)

 

16 (21)

 

Gender

                   

 Male

90

41 (46)

NS

45 (50)

NS

26 (29)

NS

27 (30)

NS

20 (22)

NS

41 (46)

NS

22 (24)

NS

17 (19)

NS

16 (18)

NS

 Female

65

30 (46)

 

34 (52)

 

24 (37)

 

14 (22)

 

10 (15)

 

23 (35)

 

18 (28)

 

16 (25)

 

9 (4)

 

Site

                   

 Colon

106

45 (42)

NS

52 (49)

NS

34 (32)

NS

29 (27)

NS

20 (19)

NS

40 (38)

NS

25 (24)

NS

23 (22)

NS

19 (18)

NS

 Rectum

49

26 (53)

 

27 (55)

 

16 (33)

 

12 (24)

 

10 (20)

 

24 (49)

 

15 (31)

 

10 (20)

 

6 (12)

 

Depth

                   

 pT1

12

4 (33)

0.03

4 (33)

0.004

0

0.003

1 (8)

NS

0

0.015

1 (8)

0.003

0

0.015

0

0.004

0

0.009

 pT2

29

8 (28)

 

7 (24)

 

4 (14)

 

5 (17)

 

5 (17)

 

6 (21)

 

4 (14)

 

1 (3)

 

0

 

 pT3

105

52 (50)

 

62 (59)

 

42 (40)

 

30 (29)

 

20 (19)

 

52 (50)

 

35 (33)

 

31 (30)

 

24 (23)

 

 pT4

9

7 (78)

 

6 (67)

 

4 (44)

 

5 (56)

 

5 (56)

 

5 (56)

 

1 (11)

 

1 (11)

 

1 (11)

 

Lymphatic invasion

                   

 Negative

31

9 (29)

0.044

11 (35)

NS

8 (26)

NS

7 (23)

NS

4 (13)

NS

12 (39)

NS

8 (26)

NS

3 (10)

NS

3 (10)

NS

 Positive

124

62 (50)

 

68 (55)

 

42 (39)

 

34 (27)

 

26 (21)

 

52 (42)

 

32 (26)

 

30 (24)

 

22 (18)

 

Vascular invasion

                   

 Negative

61

24 (39)

NS

25 (41)

0.05

12 (20)

0.008

15 (25)

NS

10 (16)

NS

19 (31)

0.046

8 (13)

0.005

10 (16)

NS

7 (11)

NS

 Positive

94

47 (50)

 

54 (57)

 

38 (40)

 

26 (28)

 

20 (21)

 

45 (48)

 

32 (34)

 

23 (24)

 

18 (19)

 

Lymph node status

                   

 pN0

85

37 (44)

NS

35 (41)

0.01

18 (21)

0.002

18 (21)

NS

11 (13)

0.04

34 (40)

NS

18 (21)

NS

18 (21)

NS

15 (18)

NS

 pNx

70

34 (49)

 

44 (63)

 

32 (46)

 

23 (33)

 

19 (27)

 

30 (43)

 

22 (31)

 

15 (21)

 

10 (14)

 

TNM stage

                   

 I

35

11 (31)

0.023

9 (26)

<0.001

3 (9)

<0.001

5 (14)

0.033

4 (11)

0.031

7 (20)

0.026

3 (8)

0.041

1 (3)

<0.001

0

0.005

 II

43

21 (49)

 

20 (47)

 

11 (26)

 

9 (21)

 

4 (9)

 

21 (49)

 

11 (26)

 

13 (30)

 

11 (26)

 

 III

53

22 (42)

 

31 (58)

 

20 (38)

 

16 (31)

 

14 (26)

 

23 (43)

 

17 (32)

 

8 (15)

 

7 (13)

 

 IV

24

17 (71)

 

19 (79)

 

16 (67)

 

11 (46)

 

8 (33)

 

13 (54)

 

9 (38)

 

11 (46)

 

7 (29)

 

Liver metastatis

                   

 Negative

133

55 (41)

0.001

62 (47)

0.01

35 (26)

<0.001

30 (23)

0.016

22 (17)

0.041

52 (39)

NS

32 (24)

NS

22 (17)

0.001

18 (14)

NS

 Positive

22

16 (73)

 

17 (77)

 

15 (68)

 

11 (50)

 

8 (36)

 

12 (55)

 

8 (36)

 

11 (50)

 

7 (32)

 

Recurrence

                   

 Negative

119

51 (43)

NS

55 (46)

0.037

29 (24)

<0.001

28 (24)

NS

19 (16)

NS

40 (34)

0.001

21 (18)

<0.001

18 (15)

0.002

12 (10)

0.001

 Positive

36

20 (56)

 

24 (67)

 

21 (58)

 

13 (36)

 

11 (31)

 

24 (67)

 

19 (53)

 

15 (42)

 

13 (36)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us